Imorgon och på onsdag blir det diskussioner om läkemedel i miljön nere i Bryssel

Imorgon åker jag ned till Bryssel för att under tisdagen och onsdagen föra diskussioner med industrikollegor om läkemedel i miljön. Den huvudsakliga generella diskussionen i samband med vårt möte i arbetsgruppen IAI PIETF (Inter-Association Initiative on Pharmaceuticals In the Environment Task Force, bildad av de tre europeiska läkemedelsindustriföreningenarna EFPIA – den forskande läkemedelsindustrin, MfE – generikaindustrin och AESGP – föreningen för receptfria läkemedelsproducenter) kommer att röra industriinitiativet EPS (Eco-Pharmaco-Stewardship). Jag har tidigare här på bloggen, bland annat i ett inlägg från 16 mars förra året (http://www.ansvarsblogg.se/wp-admin/post.php?post=5455&action=edit&message=10), kort berättat om EPS. I inlägget från 16 mars finns en kort YouTube-film (cirka 2 minuter) som skulle ha kunnat heta ”EPS in a nutshell”. Något mer detaljerat skulle EPS kunna beskrivas på följande sätt:

EPS in a nutshell

The pharmaceutical industry recognizes and understands concerns raised by stakeholders regarding the presence of pharmaceuticals in the environment (PIE). The major source of pharmaceuticals entering into the environment is via patient excretion following use of medicine that is taken to prevent, cure or alleviate a medical condition. A comparatively smaller contribution to PIE, stems from emissions from industry during manufacture of the pharmaceuticals. Industry is committed to playing a role in addressing PIE concerns and is actively engaged in minimizing the impact of its activities on the environment.

The Inter-Association Initiative on Pharmaceuticals in the Environment (IAI PIE) combines the expertise of the Association of the European Self-Medication Industry (AESGP), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Generic and Biosimilar medicines association (Medicines for Europe, MfE), in order to address the emerging environmental concerns. This is being done through sound assessment of current and future actions, whilst remaining mindful of patient needs and ensuring access to medicines. Founded on the principles of product stewardship, the Eco-Pharmaco-Stewardship (EPS) initiative has been developed. It considers the entire life-cycle of the medicine and addresses the roles and responsibilities of all parties involved including public services, the pharmaceuticals industry, environmental experts, doctors, pharmacists, and patients.

The EPS initiative is supported by three “pillars”, which have been identified as the initial key areas of focus for the pharmaceutical industry:

Pillar 1 – IMI iPIE project: The identification of the potential environmental risks of existing and new active pharmaceutical ingredients (API) through intelligent and targeted assessment strategies;

Pillar 2 – Manufacturing effluents management: The compilation of best industry practices enabling manufacturers to minimize risks to the environment; and,

Pillar 3 – extended ERA: The refinement of the existing environmental risk assessment (ERA) process for medicinal products to ensure that they remain up-to-date and relevant.

 

Kommentera

E-postadressen publiceras inte. Obligatoriska fält är märkta *